VolitionRx Advances Diagnostics with Feline Lymphoma Milestone and Licensing Talks

VolitionRx Limited (NYSE American: VNRX) has released a corporate update highlighting significant strides in its diagnostic pipeline. The company announced the submission of a feline lymphoma manuscript, which could trigger a potential $5 million milestone payment. This development underscores Volition’s commitment to advancing veterinary diagnostics alongside human health applications. Additionally, Volition is engaged in licensing discussions with over a dozen global diagnostic and liquid biopsy companies, signaling growing interest in its proprietary Nu.Q technology. The company’s Capture-Seq cancer detection platform is progressing through validation studies, while its sepsis-focused Nu.Q NETs program is expanding. In Europe, Volition is actively pursuing reimbursement in France for its lung cancer assay, a key step toward routine clinical use. These updates reflect Volition’s dual focus on both animal and human health, leveraging its expertise in epigenetics to develop simple, cost-effective blood tests for early disease detection and monitoring.

Volition’s pipeline includes multiple programs targeting cancers and diseases associated with NETosis, such as sepsis. The company’s subsidiaries are developing and commercializing blood tests that aim to detect and monitor diseases earlier, potentially improving patient outcomes and quality of life. With research and development centered in Belgium, and offices in the U.S. and London, Volition is positioning itself as a leader in the epigenetics field. The corporate update also highlighted the company’s ongoing efforts to secure regulatory approvals and reimbursement, which are critical for market adoption. The full press release is available at https://ibn.fm/nX9FK.

BioMedWire, a specialized communications platform, distributed this news. BioMedWire is part of the Dynamic Brand Portfolio @ IBN, which provides a range of corporate communications solutions, including press release distribution, editorial syndication to over 5,000 outlets, and social media distribution. For more information, visit BioMedWire.